Trial Profile
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Docetaxel; Irinotecan
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 09 Dec 2019 Results published in the Journal of Clinical Oncology
- 25 Oct 2019 Status changed from active, no longer recruiting to completed.
- 02 May 2019 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.